

LUNG ACCRUAL REPORT - OPEN and recently closed STUDIES

STUDY	O R P E E G N ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	# of ACT. INSTs	# of CURR IRBs
				LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS		
S0424-Molecular Epidemiology NSCLC	1 Y 1 Questionnaire & Specimen Sub	980	946	36	20	9	2	0	284	125
			946	36	20	9	2	0		
S0635-Bac, Stg IIIB/IV Bev + OSI-774	1 Y 1 OSI-774 and Bevacizumab	88	68	31	11	4	1	1	187	53
			68	31	11	4	1	1		
S0636-Adeno, IIIB/IV, Nsmk, Bev+OSI-774	1 N 1 OSI-774 and Bevacizumab	88	89	34	17	10	4	1	175	55
			89	34	17	10	4	1		
S0709-NSCLC, Adv, PRO+, OSI-774+-Chemo	1 Y 1 OSI-774	110	4	3	0	0	0	0	137	52
	2 Paclitaxel+Carboplatin+OSI-774		4	4	2	1	0	0		
			8	7	2	1	0	0		
S0720-NSCLC, Stg I, ERCC1/RRM1 to Adj Tx	1 Y 1 Specimen Submission	60	11	10	6	5	3	2	211	78
	2 Adjuvant chemotherapy		28	26	14	4	0	0		
			39	36	20	9	3	2		
S0722-Mesothelioma, RAD001	1 Y 1 Everolimus	60	29	10	9	7	4	1	155	46
			29	10	9	7	4	1		
S0802-ESCLC, Topotecan+/-AVE0005, PhII	1 Y 1 AVE0005 + topotecan	190	39	37	24	11	5	1	190	80
	2 Topotecan		39	37	22	12	5	0		
			78	74	46	23	10	1		

LUNG ACCRUAL REPORT - OPEN and recently closed STUDIES

STUDY	O R P E E G N ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	# of ACT. INSTs	# of CURR IRBs
				LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS		
S0819-NSCLC, Adv, Chemo/Bev +/-Cet	1 Y 1 Chemo+/-Bev w/o Cetuximab	1700	98	97	61	25	7	6	289	129
	2 Chemo+/-Bev w/ Cetuximab		102	101	56	24	13	3		
			200	198	117	49	20	9		
S0905-Mesothem,cediranib+chemo,PhI/II	1 Y 1 Pemetrexed+CDDP+Cediranib 30mg	128	5	5	5	4	2	1	2	3
			5	5	5	4	2	1		
C140503-NSCL, Lobect v Sublobar resect	1 E Total Registrations		9	5	3	1	0	0	97	40
			9	5	3	1	0	0		
C30610-SCLC, Thoracic RT	1 E Total Registrations		19	7	4	4	0	0	161	78
			19	7	4	4	0	0		
E1505-Stg IB-IIIA chemo +/- Bev	1 E Total Registrations		140	53	30	18	8	3	385	202
			140	53	30	18	8	3		

16 rows selected.

no rows selected

LUNG Recently Closed Studies Accrual Report

O
P

E DATE		REG. ARM		TOTAL	REGS.	REGS.
N CLOSED	STUDY			REGS.	LAST 30 DAYS	LAST 7 DAYS
N 01-Sep-10	S0636-Adeno, IIIB/IV, Nsmk, Bev+OSI-774	1	1 OSI-774 and Bevacizumab	89	4	1
				89	4	1

1 row selected.

LUNG SEGMENT ACCRUAL REPORT - OPEN and recently closed STUDIES

STUDY	O R P E E G N ARM			SEGMENT	TOTAL REGS.	
S0709-NSCLC, Adv, PRO+, OSI-774+-Chemo	1	Y	1	OSI-774	01: 1 cycle of OSI-774	4
			1	OSI-774	02: 1 cycle of OSI-774	2
			2	Paclitaxel+Carboplatin+OSI-774	01: 1 cycle of Chemo + OSI-774	4
S0722-Mesothelioma, RAD001	1	Y	1	Everolimus	01: Cycle 1/Mod RECIST	29
			1	Everolimus	02: 1 cycle/Mod RECIST	19
			1	Everolimus	03: 1 cycle/Mod RECIST	10
			1	Everolimus	04: 1 cycle/Mod RECIST	7
			1	Everolimus	05: 1 cycle/Mod RECIST	3
			1	Everolimus	06: 1 cycle/Mod RECIST	2
			1	Everolimus	07: 1 cycle/Mod RECIST	1
			1	Everolimus	08: 1 cycle/Mod RECIST	1
			1	Everolimus	09: 1 cycle/Mod RECIST	1
			1	Everolimus	10: 1 cycle/Mod RECIST	1
S0802-ESCLC, Topotecan+/-AVE0005, PhII	1	Y	1	AVE0005 + topotecan	01: Cycle 1	39
			1	AVE0005 + topotecan	02: Cycle 1	18
			1	AVE0005 + topotecan	03: Cycle 1	4
			1	AVE0005 + topotecan	04: Cycle 1	3
			1	AVE0005 + topotecan	05: Cycle 1	2
			1	AVE0005 + topotecan	06: Cycle 1	1
			1	AVE0005 + topotecan	07: Cycle 1	1
			1	AVE0005 + topotecan	08: Cycle 1	1
			2	Topotecan	01: Cycle 1	39
			2	Topotecan	02: Cycle 1	18
			2	Topotecan	03: Cycle 1	3
			2	Topotecan	04: Cycle 1	3
			2	Topotecan	05: Cycle 1	1
			2	Topotecan	06: Cycle 1	1
		2	Topotecan	10: Cycle 1	1	
S0819-NSCLC, Adv, Chemo/Bev +/-Cet	1	Y	1	Chemo+/-Bev w/o Cetuximab	01: Cycle 1 chemo w/o cetuximab	97
			1	Chemo+/-Bev w/o Cetuximab	02: Cycle 2 chemo w/o cetuximab	64

LUNG SEGMENT ACCRUAL REPORT - OPEN and recently closed STUDIES

STUDY	O R P E E			SEGMENT	TOTAL REGS.
	G	N	ARM		
S0819-NSCLC, Adv, Chemo/Bev +/-Cet	1	Y	1	Chemo+/-Bev w/o Cetuximab	03: Cycle 3 chemo w/o cetuximab 44
			1	Chemo+/-Bev w/o Cetuximab	04: Cycle 4 chemo w/o cetuximab 38
			1	Chemo+/-Bev w/o Cetuximab	05: Cycle 5 chemo w/o cetuximab 31
			1	Chemo+/-Bev w/o Cetuximab	06: Cycle 6 chemo w/o cetuximab 21
			1	Chemo+/-Bev w/o Cetuximab	07: Bevacizumab 7
			1	Chemo+/-Bev w/o Cetuximab	08: Bevacizumab 4
			1	Chemo+/-Bev w/o Cetuximab	09: Bevacizumab 1
			1	Chemo+/-Bev w/o Cetuximab	10: Bevacizumab 1
			1	Chemo+/-Bev w/o Cetuximab	11: Bevacizumab 1
			2	Chemo+/-Bev w/ Cetuximab	01: Cycle 1 chemo+cetuximab 100
			2	Chemo+/-Bev w/ Cetuximab	02: Cycle 2 chemo+cetuximab 61
			2	Chemo+/-Bev w/ Cetuximab	03: Cycle 3 chemo+cetuximab 47
			2	Chemo+/-Bev w/ Cetuximab	04: Cycle 4 chemo+cetuximab 38
			2	Chemo+/-Bev w/ Cetuximab	05: Cycle 5 chemo+cetuximab 24
			2	Chemo+/-Bev w/ Cetuximab	06: Cycle 6 chemo+cetuximab 18
			2	Chemo+/-Bev w/ Cetuximab	07: Cetuximab +/- Bevacizumab 12
			2	Chemo+/-Bev w/ Cetuximab	08: Cetuximab +/- Bevacizumab 10
			2	Chemo+/-Bev w/ Cetuximab	09: Cetuximab +/- Bevacizumab 6
			2	Chemo+/-Bev w/ Cetuximab	10: Cetuximab +/- Bevacizumab 5
			2	Chemo+/-Bev w/ Cetuximab	11: Cetuximab +/- Bevacizumab 4
			2	Chemo+/-Bev w/ Cetuximab	12: Cetuximab +/- Bevacizumab 3
			2	Chemo+/-Bev w/ Cetuximab	13: Cetuximab +/- Bevacizumab 1
			2	Chemo+/-Bev w/ Cetuximab	14: Cetuximab +/- Bevacizumab 1
			2	Chemo+/-Bev w/ Cetuximab	15: Cetuximab +/- Bevacizumab 1
S0905-Mesothem, cediranib+chemo, PhI/II	1	Y	1	Pemetrexed+CDDP+Cediranib 30mg	01: Cohort 1, 30mg 5
			1	Pemetrexed+CDDP+Cediranib 30mg	02: Cohort 1, 30mg 1